WHAT IS CLAIMED IS:

1. Use of:~~A method of treating a disease or disorder selected from graft versus host disease (GVHD), restrictive allograft syndrome (RAS), chronic lung allograft dysfunction (CLAD) (*e.g.*, bronchiolitis obliterans syndrome (BOS)), and systemic sclerosis (scleroderma) in a subject, comprising administering to the subject:~~

(i) a JAK inhibitor; and

(ii) a ROCK inhibitor;

in the manufacture of a medicament for the treatment of a disease or disorder selected from graft versus host disease (GVHD), restrictive allograft syndrome (RAS), chronic lung allograft dysfunction (CLAD), bronchiolitis obliterans syndrome (BOS), and systemic sclerosis (scleroderma).

2. Use of a JAK inhibitor in the manufacture of a medicament for the treatment of a disease or disorder selected from graft versus host disease (GVHD), restrictive allograft syndrome (RAS), chronic lung allograft dysfunction (CLAD), bronchiolitis obliterans syndrome (BOS), and systemic sclerosis (scleroderma), wherein the medicament is to be administered with a ROCK inhibitor.

3. Use of a ROCK inhibitor in the manufacture of a medicament for the treatment of a disease or disorder selected from graft versus host disease (GVHD), restrictive allograft syndrome (RAS), chronic lung allograft dysfunction (CLAD), bronchiolitis obliterans syndrome (BOS), and systemic sclerosis (scleroderma), wherein the medicament is to be administered with a JAK inhibitor.

~~2.~~4. The ~~method~~ use of any one of claims 1 to 3, whereint the JAK inhibitor is a selective JAK1 inhibitor.

~~3.~~5. The ~~method~~ use of any one of claims 1 to 4~~or 2~~, wherein the JAK inhibitor is selective for JAK1 over JAK2, JAK3, and TYK2.

~~4.~~6. The ~~method~~ use of any one of claims 1 to ~~3~~4, wherein the JAK inhibitor is selected from:

{1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile;

4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-1-yl}-N-[4-fluoro-2-(trifluoromethyl)phenyl]piperidine-1-carboxamide;

[3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-1-(1-{[2-(trifluoromethyl)pyrimidin-4-yl]carbonyl}piperidin-4-yl)azetidin-3-yl]acetonitrile;

4-[3-(cyanomethyl)-3-(3',5'-dimethyl-1H,1'H-4,4'-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide;

((2R,5S)-5-{2-[(1R)-1-hydroxyethyl]-1H-imidazo[4,5-d]thieno[3,2-b]pyridin-1-yl}tetrahydro-2H-pyran-2-yl)acetonitrile;

3-[1-(6-chloropyridin-2-yl)pyrrolidin-3-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile;

3-(1-[1,3]oxazolo[5,4-b]pyridin-2-ylpyrrolidin-3-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile;

4-[(4-{3-cyano-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propyl}piperazin-1-yl)carbonyl]-3-fluorobenzonitrile;

4-[(4-{3-cyano-2-[3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrol-1-yl]propyl}piperazin-1-yl)carbonyl]-3-fluorobenzonitrile;

[*trans*-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-(4-{[2-(trifluoromethyl)pyrimidin-4-yl]carbonyl}piperazin-1-yl)cyclobutyl]acetonitrile;

{*trans*-3-(4-{[4-[(3-hydroxyazetidin-1-yl)methyl]-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}acetonitrile;

{*trans*-3-(4-{[4-{[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]methyl}-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}acetonitrile;

{*trans*-3-(4-{[4-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]methyl}-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}acetonitrile;

4-(4-{3-[(dimethylamino)methyl]-5-fluorophenoxy}piperidin-1-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile;

5-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-1-yl}-N-isopropylpyrazine-2-carboxamide;

4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-1-yl}-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide;

5-{3-(cyanomethyl)-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-1-yl]azetidin-1-yl}-N-isopropylpyrazine-2-carboxamide;

{1-(*cis*-4-{[6-(2-hydroxyethyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile;

{1-(*cis*-4-{[4-[(ethylamino)methyl]-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile;

{1-(*cis*-4-{[4-(1-hydroxy-1-methylethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile;

{1-(*cis*-4-{[4-{[(3R)-3-hydroxypyrrolidin-1-yl]methyl}-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile;

{1-(*cis*-4-{[4-{[(3S)-3-hydroxypyrrolidin-1-yl]methyl}-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile;

{*trans*-3-(4-{[4-({[(1S)-2-hydroxy-1-methylethyl]amino}methyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}acetonitrile;

{*trans*-3-(4-{[4-({[(2R)-2-hydroxypropyl]amino}methyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}acetonitrile;

{*trans*-3-(4-{[4-({[(2S)-2-hydroxypropyl]amino}methyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}acetonitrile; and

{*trans*-3-(4-{[4-(2-hydroxyethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl}acetonitrile;

or a pharmaceutically acceptable salt thereof.

~~5.~~7. The ~~method~~ use of any one of claims 1 to ~~3~~5, wherein the JAK inhibitor is {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof.

~~6.~~8. The ~~method~~ use of any one of claims 1 to ~~3~~5, wherein the JAK inhibitor is {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile adipic acid salt.

~~7.~~9. The ~~method~~ use of any one of claims 1 to 3, wherein the JAK inhibitor is a JAK1/2 inhibitor.

~~8.~~10. The ~~method~~ use of any one of claims 1 to 3 or claim 9~~7~~, wherein the JAK inhibitor is (*R*)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile, or a pharmaceutically acceptable salt thereof.

~~9.~~11. The ~~method~~ use of any one of claims 1 to 3 or claim 9~~7~~, wherein the JAK inhibitor is (*R*)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate.

~~10~~12. The ~~method~~ use of ~~any one of~~ claim~~s~~ 1 or claim 2~~ to 9~~, wherein the medicament~~JAK inhibitor~~ is to be administered to the subject, and comprises the JAK inhibitor at ~~in~~ a dose of about 100 mg to about 300 mg.

13. The use of claim 3, wherein the JAK inhibitor is to be administered to the subject at a dose of about 100 mg to about 300 mg.

~~11~~14. The ~~method~~ use of ~~any one of~~ claim~~s~~ 1 or claim 2~~to 9~~, wherein the medicament~~JAK inhibitor~~ is to be administered to the subject, and comprises the JAK inhibitor at ~~in~~ a dose of about 200 mg.

15. The use of claim 3, wherein the the JAK inhibitor is to be administered to the subject at a dose of about 200 mg.

~~12~~16. The ~~method~~ use of any one of claims 1 to ~~11~~15, wherein the ROCK inhibitor is a ROCK2 inhibitor.

~~13~~17. The ~~method~~ use of claim ~~12~~16, wherein the ROCK2 inhibitor is 2-(3-(4-((1H-indazol-5-yl)amino)quinazolin-2-yl)phenoxy)-N-isopropylacetamide, or a pharmaceutically acceptable salt thereof.

~~14.~~ 18. The ~~method~~ use of ~~any one of~~ claim~~s~~ 1 or claim 3~~to 13~~, wherein the medicament ~~ROCK inhibitor~~ is to be administered to the subject, and comprises ROCK inhibitor at ~~is~~ a dose of about 200 mg/kg to about 300 mg/kg.

19. The use of claim 2, wherein the ROCK inhibitor is to be administered to the subject at a dose of about 200 mg/kg to about 300 mg/kg.

~~15~~20. The ~~method~~ use of ~~any one of~~ claim~~s~~ 1 or claim 3~~to 13~~, wherein the medicament~~ROCK inhibitor~~ is to be administered to the subject, and comprises the ROCK inhibitor at ~~is~~ a dose of about 200 mg/kg.

21. The use of claim 2, wherein the ROCK inhibitor is to be administered to the subject at a dose of about 200 mg/kg.

~~16~~22. The ~~method~~ use of ~~any one of~~ claim~~s~~ 1 or claim 2~~to 15~~, wherein the medicament comprising the JAK inhibitor is to be administered to the subject once daily.

23. The use of claim 3, wherein the JAK inhibitor is to be administered to the subject once daily.

~~17~~24. The ~~method~~ use of ~~any one of~~ claim~~s~~ 1 or claim 2~~to 15~~, wherein the medicament comprising the JAK inhibitor is to be administered to the subject orally, once daily.

25. The use of claim 3, wherein the JAK inhibitor is to be administered to the subject orally, once daily.

~~18~~26. The ~~method~~ use of ~~any one of~~ claim~~s~~ 1 or claim 2~~to 15~~, wherein the medicament comprising the JAK inhibitor is to be administered to the subject twice daily.

27. The use of claim 3, wherein the the JAK inhibitor is to be administered to the subject twice daily.

~~19~~28. The ~~method~~ use of ~~any one of~~ claim~~s~~ 1 or claim 2~~to 15~~, wherein the medicament comprising the JAK inhibitor is to be administered to the subject orally, twice daily.

29. The use of claim 3, wherein the JAK inhibitor is to be administered to the subject orally, twice daily.

~~20~~30. The ~~method~~ use of ~~any one of~~ claim~~s~~ 1 or claim 3~~to 19~~, wherein the medicament comprising the ROCK inhibitor is to be administered to the subject once daily.

31. The use of claim 2, wherein the ROCK inhibitor is to be administered to the subject once daily.

~~21~~32. The ~~method~~ use of ~~any one of~~ claim~~s~~ 1 or claim 3~~to 19~~, wherein the medicament comprising the ROCK inhibitor is to be administered to the subject orally, once daily.

33. The use of claim 2, wherein the ROCK inhibitor is to be administered to the subject orally, once daily.

~~22~~34. The ~~method~~ use of ~~any one of~~ claim~~s~~ 1 or claim 3~~to 19~~, wherein the medicament comprising the ROCK inhibitor is to be administered to the subject twice daily.

35. The use of claim 2, wherein the ROCK inhibitor is to be administered to the subject twice daily.

~~23~~36. The ~~method~~ use of ~~any one of~~ claim~~s~~ 1 or claim 3~~to 19~~, wherein the medicament comprising the ROCK inhibitor is to be administered to the subject orally, twice daily.

37. The use of claim 2, wherein the ROCK inhibitor is to be administered to the subject orally, twice daily.

~~24~~38. The ~~method~~ use of ~~any one of~~ claim~~s~~ 1~~ to 15~~, wherein the medicament comprising the JAK inhibitor and the ROCK inhibitor ~~are each~~is to be administered to the subject orally, twice daily.

~~25~~39. The ~~method~~ use of any one of claims 1 to ~~24~~38, wherein the disease or disorder is graft versus host disease.

~~26~~40. The ~~method~~ use of claim ~~25~~39, wherein the graft versus host disease is chronic graft versus host disease.

~~27~~41. The ~~method~~ use of claim ~~25~~39, wherein the graft versus host disease is sclerodermatous chronic graft versus host disease.

~~28~~42. The ~~method~~ use of any one or claims 1 to ~~27~~41, wherein the medicament is to be administered~~administration of the JAK inhibitor and ROCK inhibitor~~ to the subject and provides a reduction in the GVHD score

of the subject compared to the GVHD score of the subject prior ~~to~~to the subject being administered the medicament ~~administration of the JAK inhibitor and ROCK inhibitor~~.

~~29~~43. Use of ~~A method of treating sclerodermatous chronic graft versus host disease in a subject, comprising administering to the subject~~ {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile adipic acid salt; and 2-(3-(4-((1H-indazol-5-yl)amino)quinazolin-2-yl)phenoxy)-N-isopropylacetamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of sclerodermatous chronic graft versus host disease.

~~30~~44. Use of ~~A method of treating sclerodermatous chronic graft versus host disease in a subject, comprising administering to the subject~~ (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate; and 2-(3-(4-((1H-indazol-5-yl)amino)quinazolin-2-yl)phenoxy)-N-isopropylacetamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of sclerodermatous chronic graft versus host disease.

~~31~~45. The ~~method~~ use of ~~any one of~~ claim~~s~~ ~~2~~1 ~~to 30~~, wherein the medicament~~JAK inhibitor~~ and the ROCK inhibitor are to be administered ~~to~~ simultaneously.

~~32~~46. The ~~method~~ use of ~~any one of~~ claim~~s~~ ~~2~~1 ~~to 30~~, wherein the medicament~~JAK inhibitor~~ and the ROCK inhibitor are to be administered ~~to~~ sequentially.

47. The use of claim 3, wherein the medicament and the JAK inhibitor are to be administered simultaneously.

48. The use of claim 3, wherein the medicament and the JAK inhibitor are to be administered sequentially.